Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q2 2020 Earnings Conference Call August 5, 2020 8:30 AM ET
Company Participants
Christine Cassiano – Chief Communications Officer
David Chang – President and Chief Executive Officer
Rafael Amado – Executive Vice President-Research and Development and Chief Medical Officer
Eric Schmidt – Chief Financial Officer
Conference Call Participants
Phil Nadeau – Cowen and Company
Andrea Tan – Goldman Sachs
Biren Amin – Jefferies
Gavin Scott – JPMorgan
Tyler Van Buren – Piper Sandler
Aaron Welch – H.C. Wainwright
Mark Breidenbach – Oppenheimer
John Newman – Canaccord
Operator
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to Allogene Therapeutics Second Quarter 2020 Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be aware that today's conference call is being recorded.
I would now like to turn the call over to Christine Cassiano, Chief Communications Officer. Ms. Cassiano, please go ahead.
Christine Cassiano
Thank you, operator, and good morning. Before market opened today, Allogene issued a press release that provides a corporate update and financial results for the second quarter ended June 30, 2020. This press release is available on our website at www.allogene.com.
We remind listeners that today's call is being webcast on our website and will be available for replay. Joining me on the call today are Dr. David Chang, President and Chief Executive Officer; Dr. Rafael Amado, Executive Vice President of Research and Development and Chief Medical Officer; and Dr. Eric Schmidt, Chief Financial Officer.
We continue to conduct calls from different locations. So we appreciate your patience should we have any technical difficulties.
During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and
- Read more current ALLO analysis and news
- View all earnings call transcripts